Peptide-Based Wound Dressings: Next-Generation Infection Control

Fifty million people worldwide suffer from severe wounds. In the United States alone, chronic wound treatment costs $25 billion annually. And the single biggest complication driving those costs? Infection.

Conventional wound dressings are mostly passive barriers. Silver-impregnated dressings and antibiotic-loaded materials have helped, but silver can damage healthy tissue at high concentrations, and antibiotic resistance is making drug-loaded dressings less effective by the year.

Antimicrobial peptides offer something different. They kill bacteria through membrane disruption, making resistance development far harder. They reduce biofilm formation. Many of them simultaneously reduce inflammation and promote tissue repair. And unlike free-floating antibiotics, AMPs can be physically embedded into dressing materials for sustained, localized delivery.

The result is a new generation of wound dressings that do not just cover wounds -- they actively fight infection while helping tissue heal.

Why AMPs Make Sense for Wound Dressings

Antimicrobial peptides bring several properties that align perfectly with wound care needs:

Broad-spectrum killing. Chronic wounds are often infected by multiple organisms simultaneously -- gram-positive Staphylococcus aureus, gram-negative Pseudomonas aeruginosa, and fungi like Candida species. AMPs hit all three.

Anti-biofilm activity. Up to 78% of chronic wounds contain bacterial biofilms, which increase antibiotic resistance by up to 1,000-fold. AMPs like LL-37 disrupt biofilm formation at concentrations well below their bactericidal MIC. More on this in our biofilm disruption research article.

Immunomodulation. AMPs do not just kill bacteria. LL-37 neutralizes bacterial LPS to prevent excessive inflammation, while human beta-defensin 3 promotes keratinocyte migration and proliferation to speed wound closure.

Low resistance induction. Because AMPs target fundamental membrane structures rather than specific proteins, bacteria struggle to develop resistance. In selection pressure experiments, MRSA failed to develop resistance to the wound-targeted AMP PXL150.

Dual action. Many AMPs simultaneously fight infection and promote healing -- addressing both sides of the chronic wound problem in a single molecule.

The challenge has been getting AMPs from the laboratory into functional wound dressings that maintain peptide activity over clinically relevant timeframes. That is where materials science meets peptide biology.

Hydrogel-Based AMP Dressings

Hydrogels -- water-swollen polymer networks -- are the most widely studied platform for AMP delivery in wound care. Their high water content keeps wounds moist (optimal for healing), they conform to irregular wound surfaces, and their porous structure can be engineered for controlled peptide release.

Self-Assembling Peptide Hydrogels

Some AMPs form hydrogels spontaneously. Self-assembling peptides (SAPs) arrange themselves into nanofibrillar networks that mimic the extracellular matrix, providing both structural scaffolding for cell growth and sustained antimicrobial activity.

These SAP hydrogels promote wound healing through multiple pathways: stimulating angiogenesis (new blood vessel formation), modulating reactive oxygen species, reducing inflammation, and killing bacteria. Their thermal stability and broad antimicrobial characteristics make them practical candidates for wound care products.

Multifunctional Hybrid Hydrogels

The most advanced systems combine AMPs with other therapeutic components. One formulation published in 2024 combined three elements:

Cypate-conjugated AMPs (AMP-Cypates) that kill bacteria through direct antimicrobial activity, photothermal therapy, and photodynamic therapy
Perfluorodecalin-loaded liposomes that deliver oxygen to hypoxic wound tissue
Recombinant type III collagen that provides scaffolding for tissue regeneration

This triple-action hydrogel represents the direction the field is heading: wound dressings that fight infection, deliver oxygen, and promote healing simultaneously.

Exosome-AMP Hydrogel Combinations

A 2024 study in Biomaterials reported a hydrogel wound dressing combining exosomes (cell-derived vesicles carrying growth factors) with antimicrobial peptides. The system promoted scarless wound healing through miR-21-5p-mediated functions, suggesting that AMP-exosome combinations could address both infection and scar formation -- two of the biggest challenges in wound management.

DNA Hydrogels with Embedded AMPs

Researchers have also leveraged DNA nanostructures as AMP carriers. DNA hydrogels loaded with cationic AMPs demonstrated nuclease-sensitive degradation (meaning the body's own enzymes control release timing), controlled drug release, and significant antimicrobial activity against E. coli, susceptible S. aureus, and MRSA. In vivo studies showed rapid anti-inflammatory effects and accelerated wound healing.

Electrospun Fiber Dressings

Electrospinning produces ultrafine polymer fibers (typically 100-500 nanometers in diameter) that create dressings with extremely high surface-area-to-volume ratios, excellent porosity for gas exchange, and the ability to encapsulate bioactive molecules within the fiber matrix.

LL-37-Derived Peptide Fibers

One of the most promising approaches uses click chemistry to attach Cys-KR12, a peptide motif derived from LL-37, onto electrospun silk fibroin nanofiber membranes. The silk provides mechanical strength and biocompatibility, while the LL-37 fragment delivers sustained antimicrobial activity. This approach solves a key problem: LL-37 is expensive and protease-sensitive, but the shorter KR12 fragment retains antimicrobial activity at lower cost and can be chemically stabilized on the fiber surface.

Core-Shell Nanofiber Technology

Core-shell electrospinning creates fibers with distinct inner (core) and outer (shell) layers. This architecture offers several advantages for AMP delivery:

The shell protects the peptide from premature degradation
The core provides sustained, controlled release over days to weeks
Different drugs can be loaded in core vs. shell for sequential release
Incompatible compounds can be separated in different layers

Nisin-Loaded Nanofibers

Nisin, a well-characterized antimicrobial peptide originally used in food preservation, has been incorporated into several electrospun systems. A 2024 study produced polycaprolactone-polyethylene glycol (PCL/PEG) nanofibers loaded with nisin that achieved 94.3% controlled release over 24 hours and showed activity against both S. aureus and P. aeruginosa -- the two most common wound pathogens. Cell viability was approximately 78%, confirming acceptable biocompatibility.

Separately, nisin has been immobilized on bacterial nanocellulose membranes through covalent binding and adsorption, creating dressings with activity against S. epidermidis, S. aureus, and E. faecalis without affecting human dermal fibroblast morphology.

Combining Electrospun Fibers with Hydrogels

Hybrid dressings that combine electrospun fibers with hydrogels are an active area of development. The electrospun layer provides mechanical strength and acts as a barrier, while the hydrogel maintains moisture and delivers bioactive compounds. Together, they create multifunctional dressings that no single material can achieve alone.

Peptide Stability in Electrospun Systems

One of the persistent challenges with AMP-loaded electrospun fibers is maintaining peptide activity during the electrospinning process, which involves high voltage, organic solvents, and mechanical stress. Core-shell architecture helps by encapsulating the peptide in the protected inner core, shielding it from denaturing conditions during fiber formation.

Researchers have also explored post-spinning conjugation -- electrospinning the fiber first, then attaching the AMP to the fiber surface through chemical coupling. This avoids exposing the peptide to the spinning process entirely, though it typically results in lower peptide loading compared to encapsulation methods.

The choice between encapsulation and surface conjugation affects release kinetics. Encapsulated peptides release slowly as the fiber degrades (days to weeks). Surface-conjugated peptides provide an initial burst of antimicrobial activity. Some advanced designs combine both: surface peptide for immediate killing, encapsulated peptide for sustained protection.

Smart and Responsive AMP Dressings

The next frontier is dressings that respond to the wound environment in real time.

Infection-Sensing Dressings

A wireless, flexible smart wound dressing introduced in recent research can monitor matrix metalloproteinase-9 (MMP-9), a biomarker elevated in chronic wound environments. The system uses a radio frequency sensor connected to a bioresponsive hydrogel functionalized with peptide sequences. When MMP-9 levels rise (indicating inflammation or infection), the system provides real-time monitoring while simultaneously releasing silver nanoparticles for antimicrobial activity.

This type of closed-loop system -- sense infection, deliver treatment -- represents the future of wound management.

Stimuli-Responsive Release

Researchers are developing hydrogels that release AMPs in response to specific environmental triggers:

pH-responsive systems that release peptides when wound pH drops (indicating bacterial colonization)
Temperature-responsive systems that activate when wound temperature rises (indicating inflammation)
Enzyme-responsive systems that release peptides when bacterial enzymes are detected

These approaches ensure AMPs are delivered when and where they are needed, minimizing waste and reducing the risk of toxicity from unnecessary peptide exposure.

PXL150: A Purpose-Built Wound AMP

PXL150, developed by Pergamum AB in Sweden, was designed specifically for topical wound applications and has the most extensive preclinical dataset of any wound-targeted AMP.

Mechanism. PXL150 causes rapid depolarization of the bacterial cytoplasmic membrane, killing target organisms quickly.

Spectrum. Broad-spectrum activity against gram-positive and gram-negative bacteria, including MRSA. No resistance development observed under sustained selection pressure.

Anti-inflammatory properties. PXL150 downregulates TNF-alpha and plasminogen activator inhibitor type 1 (PAI-1) secretion in human cell lines, suggesting dual antimicrobial and anti-inflammatory action.

Surgical site infections. In a mouse model, PXL150 formulated in hydroxypropyl cellulose (HPC) gel significantly reduced bacterial counts in staphylococcal surgical wounds.

Burn wounds. Four days of twice-daily PXL150 gel application significantly reduced bacterial counts in burn wound models, with pronounced anti-infective effects visible from day one post-infection.

Safety. No treatment-related mortality or systemic toxicity in repeated-dose rat studies. No ocular or cutaneous toxicity in rabbit tolerance tests.

PXL150's preclinical package is strong. Clinical translation has been slower than the data might warrant, likely reflecting the broader challenges of AMP drug development: manufacturing cost, regulatory pathway complexity, and the difficulty of securing funding for novel antibiotic classes.

Defensin-Conjugated Wound Fabrics

A 2025 study published in Communications Materials (Nature) took a different approach: rather than loading defensins into hydrogels or nanofibers, researchers conjugated defensin peptides directly onto polymer fabric. These defensin-conjugated fabrics demonstrated:

Antibacterial activity against multiple drug-resistant bacteria
Prevention of cell adhesion and biofilm formation
Promotion of wound healing

The fabric approach is attractive because it integrates into existing wound dressing manufacturing rather than requiring entirely new production platforms. Medical dressings are typically not effective at preventing bacterial invasion and act only as physical barriers -- defensin conjugation transforms them into active antimicrobial surfaces.

AMP-Coated Implant Surfaces

Beyond wound dressings, AMP-functionalized surfaces are being developed for orthopedic implants, dental implants, and catheters -- anywhere a foreign surface contacts tissue and risks biofilm formation.

Titanium Implant Coatings

Both LL-37 and hBD-3 have shown activity against staphylococcal biofilms on titanium in laboratory studies. LL-37-derived peptides (FK-16, GF-17) tested at IRCCS Istituto Ortopedico Galeazzi in Milan specifically target orthopedic implant infections -- a application where local AMP delivery from the implant surface itself could prevent the biofilm colonization that often necessitates surgical implant removal.

Surface immobilization techniques include covalent bonding (where the peptide is chemically attached to the metal or polymer surface), physical adsorption, and layer-by-layer deposition. The challenge is maintaining AMP activity after immobilization while ensuring the coating does not degrade too quickly or too slowly.

Catheter Coatings

Catheter-associated infections cause over 250,000 bloodstream infections annually in the US. Omiganan, the synthetic indolicidin analog, was originally developed as a catheter-coating antimicrobial. While its Phase 3 catheter trial did not demonstrate superiority over existing approaches, the concept of AMP-coated catheters remains active in research with newer peptides and coating technologies.

Clinical Evidence and Trials

Where the Evidence Stands

The honest assessment: most AMP wound dressing research remains at the preclinical stage. Animal model data is extensive and promising, but human clinical trials are limited.

A review of ClinicalTrials.gov entries as of December 2024 identified nine clinical studies for hydrogel-based chronic wound treatments, but only three were in Phase 4 (near-market). Most enrolled fewer than 20 participants -- too small for robust statistical conclusions.

What Has Been Tested in Humans

Pexiganan (MSI-78) cream for diabetic foot ulcers completed two Phase 3 trials but was denied FDA approval because it did not outperform existing topical treatments. However, pexiganan demonstrated broad-spectrum activity and no resistance development, suggesting the formulation or delivery -- not the peptide itself -- may need optimization.

Brilacidin for skin infections was tested intravenously (not as a dressing) and showed efficacy comparable to daptomycin, as detailed in our defensins clinical development article.

Several AMP-based wound products are in earlier-stage clinical evaluation, though detailed results have not yet been published.

The Translation Gap

The gap between preclinical promise and clinical reality is narrower than it was five years ago, but it remains the central challenge. Key issues include:

Standardized wound assessment protocols needed for regulatory approval
Scale-up of peptide-functionalized dressings from lab bench to manufacturing line
Long-term stability data for AMP-loaded materials during storage and shipping
Regulatory frameworks designed for traditional dressings that may not accommodate bioactive, peptide-releasing materials

The Market and Commercial Outlook

The global wound care market was projected to exceed $2.2 billion in 2024, with the advanced wound dressings segment expected to reach $8.3 billion by 2034. The market opportunity for AMP-based dressings is significant, especially for chronic wounds where infection is the primary driver of treatment failure and cost.

Several FDA-approved products already contain antimicrobial peptide-derived compounds for wound use:

Neosporin (contains gramicidin, a peptide antibiotic)
Bacitracin (a cyclic peptide antibiotic)
Polymyxin B (a lipopeptide antibiotic)

These precedents establish that peptide-based wound products can achieve regulatory approval, even if the newer AMP-functionalized dressing technologies are more sophisticated.

MPM Medical's TriSAP, introduced in 2025, combines silicone, silver, and super absorbency in a single dressing -- demonstrating market appetite for multifunctional wound materials. AMP-based dressings could represent the next step beyond silver technology.

AMP Dressings vs. Silver Dressings: How They Compare

Silver-based dressings are the current standard for antimicrobial wound care, but they have documented limitations:

Cytotoxicity. Silver ions can damage fibroblasts and keratinocytes at concentrations that are antimicrobially effective, potentially slowing wound healing even as they prevent infection.
Resistance. While rarer than antibiotic resistance, silver resistance genes (sil genes) have been identified in clinical bacterial isolates, particularly in burn units.
Environmental concerns. Silver nanoparticle release from wound dressings into wastewater is an emerging environmental issue.

AMP-based dressings could address all three. AMPs are generally less cytotoxic to human cells than equivalent concentrations of silver ions. The multi-target mechanism of AMPs makes resistance development harder. And peptide dressings would biodegrade naturally without heavy metal contamination.

The trade-off: AMP dressings are currently more expensive and less proven in clinical settings. Silver dressings have decades of clinical use and established manufacturing. The transition will be gradual, with AMP dressings likely entering clinical use first in high-value applications (chronic wounds, diabetic ulcers, burn care) where silver dressings have fallen short.

What This Means for Patients

AMP-loaded wound dressings are not in your local pharmacy yet. But the trajectory is clear: multiple delivery platforms (hydrogels, electrospun fibers, smart fabrics) are being optimized, preclinical data is strong across multiple AMP classes, and the market demand driven by chronic wound infections and antibiotic resistance is only growing.

For patients with chronic wounds, diabetic ulcers, or surgical site infections, AMP dressings could eventually offer something current products cannot: broad-spectrum antimicrobial protection with anti-biofilm activity, simultaneous anti-inflammatory and wound-healing effects, and minimal risk of promoting further antibiotic resistance.

The first AMP wound dressings to reach clinical use will likely combine established dressing materials (hydrogels, nanofibers) with well-characterized peptides (LL-37 derivatives, defensin mimetics, or engineered synthetic AMPs) in topical formulations that bypass the systemic delivery challenges that have slowed AMP drug development elsewhere.

For broader context on how peptides support wound healing, see our guides on best peptides for wound healing and tissue repair, best peptides for skin wound healing, and our profiles on BPC-157 and TB-500.

Related Reading on PeptideJournal.org: